Half-year report · Q2
2796.TEDINET S100V2NV
Period2024-06-01 → 2024-11-30
Filed2025-01-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥54.5bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥100m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥710m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥29m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥833m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥701m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥34m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥662m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥113m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥351m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥273m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥121m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥282m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥30.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥29.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥23.0bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥22.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.2bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥7.4bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.4bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.5bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.2bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥200m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥537m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥543m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-10.09 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-33.41 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.29 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.99 | 2023-06-01 → 2023-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.6% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥175m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥1m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥311m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥311m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥22m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥202m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥256m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥256m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥58m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥282m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥276m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥162m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥38m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥21m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥831m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥56m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥870m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥872m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 560
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |